机构:[1]Laboratory of Immunology, Institute Pasteur de Tunis and Faculty of Medicine, University Tunis El Manar, 1002 Tunis, Tunisia[2]Humanitas Clinical andResearch Center, 20089 Rozzano, Italy[3]Clinical Laboratory, Guangdong Provincial Hospital of Chinese medicine, 510000 Guangzhou, China广东省中医院[4]Division ofGastroenterology and Center for Autoimmune Liver Diseases, Department of Medicine and Surgery, University of Milan-Bicocca, 20900 Monza (MB), Italy[5]Department of Research and Development, Inova Diagnostics, 92131 San Diego, CA, USA[6]Department of Anesthesia and Intensive Care, ChildrenHospital Bechir Hamza, Tunis and Faculty of Medicine, University Tunis El Manar, 1007 Tunis, Tunisia[7]Division of Gastroenterology and Hepatology, KeyLaboratory of Gastroenterology and Hepatology, Ministry of Health, State, Key Laboratory for Oncogenes and Related Genes, Renji Hospital, School ofMedicine, Shanghai Jiao Tong University, Shanghai Institute of Digestive Disease, 200001 Shanghai, China[8]Division of Rheumatology, Allergy andClinical Immunology, University of California at Davis, 95616 Davis, CA, USA
Hyper-immunoglobulin M syndrome is an X-linked primary immunodeficiency disease caused by mutations in the CD40 ligand gene. The CD40 ligand has been recently highlighted as playing a key role in the pathogenesis of primary biliary cholangitis. In the present study, we assessed an extensive set of serum autoantibodies in a series of well-defined patients with hyper-immunoglobulin M syndrome. Serum, liver-related and liver-not-related autoantibodies IgG, IgM and IgA were tested by ELISA and standard indirect immunofluorescence in HEp-2 cells in 13 Tunisian patients (8 males and 5 females, aged 1-12 years) with hyper-immunoglobulin M syndrome during 1995-2012 and, as controls, 21 age-and gender-matched blood donors. The level of IgM antibody against MIT3 was significantly higher in patients than in controls (35.8 vs 10.7, P = 0.002). Half of the hyper-immunoglobulin M syndrome patients were found to be anti-MIT3 IgM positive vs none of the controls (P < 0.0001). Twenty-three percent of patients were found to be anti-sp100 antibody positive vs only 0.05% of controls. By immunofluorescence, 92.3% of patients were MIT3 IgM positive vs none of the controls. In conclusion, the IgM class of anti-MIT3 antibodies was shown to be present by both ELISA and immunofluorescence in most of the patients with hyper-immunoglobulin M syndrome. The presence of the hallmark of primary biliary cholangitis, a disease where the CD40 ligand is a key player, in an immunodeficiency disease caused by mutations in the CD40 ligand gene is very intriguing and opens new scenarios in understanding the immune pathogenesis of primary biliary cholangitis.
第一作者机构:[1]Laboratory of Immunology, Institute Pasteur de Tunis and Faculty of Medicine, University Tunis El Manar, 1002 Tunis, Tunisia
通讯作者:
通讯机构:[2]Humanitas Clinical andResearch Center, 20089 Rozzano, Italy[4]Division ofGastroenterology and Center for Autoimmune Liver Diseases, Department of Medicine and Surgery, University of Milan-Bicocca, 20900 Monza (MB), Italy[*1]Division of Gastroenterology and Hepatology, Center for Autoimmune Liver Diseases, Department of Medicine and Surgery, University of Milan-Bicocca, 20900 Monza (MB), Italy.
推荐引用方式(GB/T 7714):
Barbouche Mohamed-Ridha,Chen Qubo,Carbone Marco,et al.Comprehensive review of autoantibodies in patients with hyper-IgM syndrome[J].CELLULAR & MOLECULAR IMMUNOLOGY.2018,15(6):610-617.doi:10.1038/cmi.2017.140.
APA:
Barbouche, Mohamed-Ridha,Chen, Qubo,Carbone, Marco,Ben-Mustapha, Imen,Shums, Zakera...&Invernizzi, Pietro.(2018).Comprehensive review of autoantibodies in patients with hyper-IgM syndrome.CELLULAR & MOLECULAR IMMUNOLOGY,15,(6)
MLA:
Barbouche, Mohamed-Ridha,et al."Comprehensive review of autoantibodies in patients with hyper-IgM syndrome".CELLULAR & MOLECULAR IMMUNOLOGY 15..6(2018):610-617